Submitted:
07 October 2025
Posted:
08 October 2025
You are already at the latest version
Abstract
Background Gastrointestinal [GI] bleeding is a common late complication [>30 days] in Transcatheter Aortic Valve Replacement [TAVR] patients, associated with poorer long-term prognosis and mortality. Its management is complex, often requiring gastroenterology consultation. Risk factors include age, comorbidities, antiplatelet use, and altered hemodynamics, which complicate endoscopic procedures. Patients with prior GI bleeding may face delays or ineligibility for TAVR. Objectives This study aims to determine [a] whether a history or new onset of GI bleeding impacts clinical outcomes in TAVR patients on antiplatelet therapy, and [b] if selecting single antiplatelet therapy [SAPT] over DAPT worsens adverse cardiac events in patients with GI bleeds. Methods We conducted a retrospective chart review of TAVR patients from 2018-2021 at a tertiary medical center [n=470]. Patients with prior stents or anticoagulant indications were excluded [n=214]. The primary outcome was comparing adverse cardiac events in patients with and without GI bleeds. Secondary outcomes included rates and types of postoperative GI and non-GI bleeds, bleeding interventions, and all-cause mortality. Results Among patients, 3.6% on DAPT, 25% on aspirin, and 17.6% on clopidogrel had a history or developed a new GI bleed. No significant differences in adverse cardiac events were observed between those with and without GI bleeds or between SAPT and DAPT groups. Conclusions History of GI bleeds and post-TAVR anti-platelet therapy selection does not impact adverse cardiac outcomes.
Keywords:
1. Introduction
2. Materials and Methods
3. Results
3.1. Cohort Overview and Antiplatelet Exposure
3.1.1. Summary of Therapy Groups
3.2. History of Gastrointestinal [GI] Bleeding and Outcomes
3.2.1. Impact on Post-TAVR Prognosis
3.2.2. Recurrence of GI Bleeding
3.3. Comparative Effectiveness: SAPT vs DAPT
3.3.1. Adverse Cardiac and Cerebrovascular Events
3.4. Bleeding Phenotypes and Mortality Context
3.4.1. Access-Site Versus Non-Access-Site Bleeding
3.5. Safety Signals over Time
3.5.1. Contemporary Procedural Risk
3.6. Figures, Tables and Schemes


| Variable | Setting | ||
|---|---|---|---|
| History or Denovo GI Bleed n=19 |
No GI bleed n=195 |
p-value1 | |
| Adverse Cardiac Events | 3 [16%] | 14 [7.2%] | 0.181 |
| MI | 1 [5.3%] | 1 [0.5%] | 0.170 |
| Arrythmia | 2 [11%] | 12 [6.2%] | 0.359 |
| Stroke | 0 [0%] | 2 [1.0%] | >0.999 |
| 1-year Mortality | 0 [0%] | 5 [2.6%] | >0.999 |
| Permanent Pacemaker Placement | 2 [11%] | 9 [4.6%] | 0.254 |
| Other Bleeds | 0.730 | ||
| Access Site Bleed | 1 [14%] | 5 [25%] | |
| Access Site Hematoma | 3 [43%] | 8 [40%] | |
| Femoral Artery Pseudoaneurysm |
2 [29%] | 3 [15%] | |
| Pericardial Effusion | 0 [0%] | 1 [5%] | |
|
1Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test GI: Gastrointestinal; MI: Myocardial Infarction; | |||
| Variable | Setting | ||
|---|---|---|---|
| History or De novo GI Bleed n = 11 |
No GI bleed n = 38 |
p-value1 | |
| Adverse Cardiac Events | 2 [18%] | 4 [11%] | 0.605 |
| MI | 0 [0%] | 1 [2.6%] | >0.999 |
| Arrythmia | 2 [18%] | 3 [7.9%] | >0.999 |
| Stroke | 0 [0%] | 0 [0%] | |
| 1-year Mortality | 0 [0%] | 2 [5.3%] | >0.999 |
| Permanent Pacemaker Placement | 0 [0%] | 0 [0%] | |
| Other Bleeds | 0.365 | ||
| Access Site Bleed | 0 [0%] | 0 [0%] | |
| Access Site Hematoma | 3 [60%] | 2 [40%] | |
| Femoral Artery Pseudoaneurysm |
2 [40%] | 0 [0%] | |
| GU hematuria | 0 [0%] | 2 [40%] | |
| Retroperitoneal Bleed | 0 [0%] | 1 [20%] | |
|
1Statistical tests performed: Wilcoxon rank-sum test; Fisher’s exact test GI: Gastrointestinal; MI: Myocardial Infarction; | |||
4. Discussion
4.1. Rationale for Antiplatelet Therapy After TAVR
4.1.1. Historical Framework and Evolving Evidence
4.2. Synthesis with Prior Literature
4.2.1. Meta-Analyses and Randomized Data
4.3. Interpreting Our Findings in the Context of Bleeding Phenotypes
4.3.1. GI Bleeding as a Distinct Non-Access-Site Entity
4.4. Clinical Implications for Antiplatelet Selection
4.4.1. Individualized Therapy and Guideline-Concordant Care
4.5. Study Limitations
4.5.1. Design, Sample, and Data Constraints
4.6. Future Directions
4.6.1. Targeted Prospective Evaluation
5. Conclusions
Abbreviations
| Transcatheter Aortic Valve Replacement | (TAVR) |
| Dual Anti-Platelet Therapy | (DAPT) |
| Single Anti-Platelet Therapy | (SAPT) |
| Aspirin | (ASA) |
| Gastrointestinal | (GI) |
| Upper Gastrointestinal Bleed | (UGIB) |
| Lower Gastrointestinal Bleed | (LGIB) |
| Myocardial Infarction | (MI) |
| Oral Anti-Coagulation | (OAC) |
| Proton Pump Inhibitor | (PPI) |
References
- Eckstein J, Liu S, Toleva O, Yanagawa B, Verma S, Cheema AN. Antithrombotic therapy after transcatheter aortic valve replacement: current perspective. Curr Opin Cardiol. 2021 Mar 1;36[2]:117-124. [CrossRef]
- Keskinbora KH, Keskinbora K. A systematic review of Ibn Sina's [Avicenna] studies: reflections on anatomy. Eur J Anat. 2016;20[1]:99–105.
- Zhang Y, Shen L, Yang W, He B. Dual antiplatelet therapy vs. single antiplatelet therapy after transcatheter aortic valve replacement: an updated systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:679703. [CrossRef]
- Moey MYY, Udani K, Nifong LW, Carabello BA, Morris DL, Shah NN. Optimal antiplatelet and antithrombotic regimen post-transcatheter aortic valve replacement. Eur J Clin Invest. 2023;53:e14071. [CrossRef]
- Piccolo R, Pilgrim T, Franzone A, Valgimigli M, Haynes A, Asami M, Lanz J, Räber L, Praz F, Langhammer B, Roost E, Windecker S, Stortecky S. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10[14]:1436-1446. [CrossRef]
- Kamboj AK, Hoversten P, Leggett CL. Upper gastrointestinal bleeding: etiologies and management. Mayo Clin Proc. 2019;94[4]:697-703. [CrossRef]
- Aoki T, Hirata Y, Yamada A, Koike K. Initial management for acute lower gastrointestinal bleeding. World J Gastroenterol. 2019;25[1]:69-84. [CrossRef]
- Lu C, Zhang Y. Gastrointestinal bleeding during the transcatheter aortic valve replacement perioperative period: A review. Medicine [Baltimore]. 2022;101[48]:e31953. [CrossRef]
- Raheja H, Garg A, Goel S, et al. Comparison of single versus dual antiplatelet therapy after TAVR: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;00:1–9. [CrossRef]
- Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;383[15]:1447-1457. [CrossRef]
- Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;382[18]:1696-1707. [CrossRef]
- Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE [Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation] Randomized Clinical Trial. JACC Cardiovasc Interv. 2017;10[13]:1357-1365. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).